GEP-NET
Clinical trials for GEP-NET explained in plain language.
Never miss a new study
Get alerted when new GEP-NET trials appear
Sign up with your email to follow new studies for GEP-NET, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for gut cancer patients who failed standard therapy
Disease control Recruiting nowThis study tests a new drug called RYZ101 in people with advanced neuroendocrine tumors of the gut or pancreas that have grown after prior treatment with a standard radioactive therapy. The goal is to see if RYZ101 can slow tumor growth better than other available treatments. Abo…
Matched conditions: GEP-NET
Phase: PHASE3 • Sponsor: RayzeBio, Inc. • Aim: Disease control
Last updated May 17, 2026 04:15 UTC
-
Radioactive drug RYZ401 targets Hard-to-Treat tumors in first human trial
Disease control Recruiting nowThis early-stage study tests a new radioactive drug called RYZ401 in people with neuroendocrine tumors and other solid tumors that have a specific protein on their surface. The main goals are to find the safest dose and schedule, and to see if the drug can shrink tumors. About 10…
Matched conditions: GEP-NET
Phase: PHASE1 • Sponsor: RayzeBio, Inc. • Aim: Disease control
Last updated May 15, 2026 11:57 UTC
-
450 patients join study to personalize neuroendocrine tumor care
Knowledge-focused Recruiting nowThis study looks at how things like age, sex, tumor grade, and location affect how well treatments work for people with well-differentiated gastroenteropancreatic neuroendocrine tumors (GEP-NENs). Researchers will track 450 adults who have received standard therapies like somatos…
Matched conditions: GEP-NET
Sponsor: IRCCS San Raffaele • Aim: Knowledge-focused
Last updated May 04, 2026 16:22 UTC